Love Reginald sold $29K of SRTA

Love Reginald sold 5,091 shares of Strata Critical Medical, Inc. (SRTA) at $5.75 on 2026-08-10.

Original reporting
SEC EDGAR · Love Reginald
Published Aug 13, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRTA
Neutral
low confidence
Mentioned
$SRTA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTANeutralLow
01

Why it matters

The only new information is the reported open-market sale by a director, including share count, price, and post-transaction holdings.

02

Market read

Traders may briefly reassess sentiment around SRTA due to the insider sale disclosure, but there is no accompanying fundamental catalyst.

03

What to watch

The sale size is modest and the article provides no context on liquidity needs, diversification, or whether other insiders are selling/buying.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-08-13, covering a sale dated 2026-08-10.

Background

The article is an SEC Form 4 insider transaction disclosure for Strata Critical Medical, Inc.

Company-level read

Ticker impact

$SRTANeutralLow confidence
Context

Strata Critical Medical director Love Reginald sold 5,091 shares in an open-market transaction for about $29.3K, per Form 4 filed today.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless paired with other material news.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no company-specific operational or financial change.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as less mechanical selling, potentially increasing short-term scrutiny.

Key entities

  • Strata Critical Medical, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Love Reginald

    Director who sold 5,091 shares at $5.7500 on 2026-08-10.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRTAMed

Strata Critical Medical (SRTA) Q3 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q3 2026 earnings, exceeding guidance with 20% sequential revenue growth in clinical services, $8.6M in free cash flow, and $42M in cash. The company announced a $20M share repurchase program and expects high-teens organic EBITDA growth in 2027. Strata completed acquisitions and aims to deploy additional capital strategically.

$SRTAMed

Strata Critical Medical Q3 Earnings Call Highlights

Strata Critical Medical (SRTA) reported Q3 clinical gross profit up 18.3% sequentially, but gross margin declined to 25.6%. Logistics revenue fell 6.9% sequentially, while gross margin improved to 20.8%. The company expects higher margins in 2027. Strata ended the quarter with $41.6M in cash and authorized a $20M share repurchase. It reiterated 2026 guidance and expects high-teens organic adjusted EBITDA growth in 2027.

$SRTAMed

Strata Critical Medical Announces Third Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 November 3, 2026 Strata Critical Medical Announces Third Quarter 2026 Results • Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 • Q3 2026 net loss from continuing operations of $

$SRTAMedAI 8/10

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q2 2026 results, citing 15.1% sequential organic clinical revenue growth, with Transplant Clinical up 23.8%. Clinical gross margin rose to 26.1%. It generated $5.7M operating cash flow and $2.9M free cash flow. The company completed three bolt-on acquisitions and expects stronger cash generation in H2.

$SRTAMed

Strata Critical Medical Announces Second Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clini